Single Ascending Dose, First-in-Human Study on Safety, Tolerability and Pharmacokinetics of BAY1161116

Inclusion Criteria: * Healthy female postmenopausal subjects * Age: 45 to 65 years (inclusive) * Body mass index (BMI) : ≥18 and ≤30 kg/m² * Non-smoker for 3 months (former smokers who quit smoking \>3 months before the first study drug administration may be included) Exclusion Criteria: * Incomplete recovery from pre-existing disease for which it can be assumed that the absorption, distribution, excretion,and effect of the study drugs will not be normal * Any use of systemic or topically active medication or herbal remedies, prescription or non-prescription, from screening to the first drug administration (occasional use of paracetamol or ibuprofen is permissible) * Any severe disease within the last 4 weeks prior to the first study drug administration * History of orthostatic hypotension, fainting spells, blackouts * Any malignant tumor and history thereof * Any other medical condition which, at the discretion of the investigator, would make study participation unadvisable * Any clinically relevant finding at the physical- and gynecological examinations * Allergy, hypersensitivity, or non-allergic drug reactions to any excipient of the IMP or reference/interaction product * Regular alcohol consumption equivalent to \>20 g alcohol per day * Urine screen positive for any drug or cotinine